.

Biotav is a pioneering force in biotechnology research, dedicated to developing innovative solutions for critical health challenges. With a strong foundation in veterinary medicine, Biotav has successfully adapted its expertise to human medicine, embodying the ‘One Health’ approach. The company leverages three decades of rigorous research, development, and manufacturing experience to address emerging infectious diseases and oncological needs.

Located in Migdal Haemek, ISRAEL, at Mifaley Haemek BOX 73, 2310000, Biotav is at the forefront of creating groundbreaking treatments. Currently, Biotav is focused on developing an oncological viral treatment for brain tumors, alongside a vaccine and treatment for COVID-19. Their state-of-the-art production facility operates in accordance with GMP standards, ensuring the highest quality in pharmaceutical development.

Biotav's commitment to transforming the treatment of emerging infectious diseases is supported by provisional patents and pending applications, complemented by an extensive network of connections with leading institutes and government offices. Biotav is poised to make significant advancements in the biotechnology landscape, continually pushing the boundaries of medical science. We invite the company's management to create a customized and exclusive company showcase and product listing on our platform to further enhance Biotav's visibility and commercial opportunities.